Molecular analysis of premalignant and carcinoma in situ lesions of the human breast

American Journal of Pathology

Volumn 149, Issue 3, 1996, Pages 733-738

  Steeg, Patricia S ^a   Clare, Susan E ^a   Lawrence, Julia A ^a   Zhou, Qun ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLINE; ESTROGEN RECEPTOR; MESSENGER RNA; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA1;

BREAST CARCINOGENESIS; BREAST CARCINOMA; CARCINOMA IN SITU; GENE MUTATION; HIGH RISK PATIENT; HUMAN; PRECANCER; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

ANIMALS; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; CYCLINS; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, P53; HUMANS; MOLECULAR PROBE TECHNIQUES; PRECANCEROUS CONDITIONS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029746711     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. DuPont W, Page D: Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985, 312:146-151
2. Page D: Cancer risk assessment in benign breast biopsies. Hum Pathol 1986, 17:871-874
3. Otteson GL, Graversen HP, Blichert TM, Zedeler K, Andersen JA: Ductal carcinoma in situ of the female breast: short term results of a prospective nationwide study. Am J Surg Pathol 1992, 16:1183-1196
4. Ward BA, McKhann CF, Ravikkumar TS: Ten year follow-up of breast carcinoma in situ in Connecticut. Arch Surg 1992, 127:1392-1395
5. Schnitt SJ, Connolly JL, Tavassoli FA, Fechner RE, Kempson RL, Gelman R: Interobserver reproducibility in the diagnosis of ductal proliferative breast lesions using standardized criteria. Am J Surg Pathol 1992, 16:1133-1143
6. Morrow M, Schnitt SJ, Harris JR: In situ carcinomas. Diseases of the Breast. Edited by ME Lippman, M Morrow, S Hellman. New York, Lippincott-Raven Publishers, 1996, pp 355-368
7. Dawson P, Wolman S, Tait L, Heppner G, Miller F: MCF10AT. A model for the evolution of cancer from proliferative breast disease. Am J Pathol 1996, 148:1-7
8. Millikan R, Hulka B, Thor A, Zhang Y, Edgerton S, Zhang X, Pei H, He M, Wold L, Melton L, Ballard D, Conway K, Liu E: p53 mutations in benign breast tissue. J Clin Oncol 1995, 13:2293-2300
9. Volpert OV, Stellmach V, Bouck N: The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression. Breast Cancer Res Treat 1995, 36:119-126
10. Band V: Preneoplastic transformation of human mammary epithelial cells. Semin Cancer Biol 1995, 6:185-192
11. Guy C, Webster M, Schaller M, Parsons T, Cardiff R, Muller W: Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 1992, 89: 10578-10582
12. Muller W, Sinn E, Pattengale P, Wallace R, Leder P: Single step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 1988, 54:105-115
13. Bouchard L, Lamarre L, Tremblay PJ, Jolicoeur P: Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell 1989, 57:931-936
14. Yu D, Matin A, Xia W, Sorgi F, Huang L, Hung MC: Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu. Oncogene 1995, 5:1383-1388
15. Yu D, Wang SS, Dulski KM, Tsai CM, Nicolson GL, Hung MC: c-erb-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res 1994, 54:3260-3266
16. Yu D, Shi D, Scanlon M, Hung MC: Reexpression of neu-encoded oncoprotein counteracts the tumor-suppressing but not the metastasis-suppressing function of E1A. Cancer Res 1993, 53:5784-5790
17. Stratton M, Collins N, Lakhani S, Sloane J: Loss of heterozygosity in ductal carcinoma in situ of the breast. J Pathol 1995, 175:195-201
18. Radford D, Fair K, Thompson A, Ritter J, Holt M, Steinbrueck T, Wallace M, Wells JSA, Donis-Keller H: Allelic loss on chromosome 17 in ductal carcinoma in situ of the breast. Cancer Res 1993, 53:2947-2950
19. Radford D, Fair K, Phillips N, Ritter J, Steinbrueck T, Holt M, Donnis-Keller H: Allelotyping of ductal carcinoma in situ of the breast: deletion of loci on 8p, 13q, 16q, 17p, and 17q. Cancer Res 1995, 55:3399-3405
20. O'Connell P, Pekkel V, Fuqua S, Osborne C, Allred D: Molecular genetic studies of early breast cancer evolution. Breast Cancer Res Treat 1994, 32:5-12
21. Tsuda H, Fukutomi T, Hirohashi S: Pattern of gene alterations in intraductal breast neoplasms associated with histological type and grade. Clin Cancer Res 1995, 1:261-267
22. Weinstat-Saslow D, Merino MJ, Manrow RE, Lawrence JA, Bluth RF, Wittenbel KD, Simpson JF, Page DL, Steeg PS: Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nature Med 1995, 1:1257-1260
23. Sicinski P, Donaher J, Parker S, Li T, Fazeli A, Gardner H, Haslam S, Bronson R, Elledge S, Weinberg R: Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 1995, 82:621-630
24. Parham D, Jankowski J: Transforming growth factor-α in epithelial proliferative diseases of the breast. J Clin Pathol 1992, 45:513-516
25. Brown L, Berse B, Jackman R, Tognazzi K, Guidi A, Dvorak H, Senger D, Connolly J, Schnitt S: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995, 26:86-91
26. Guidi A, Fischer L, Harris J, Schnitt S: Microvessel density and distribution in ductal carcinoma in situ of the breast. J Natl Cancer Inst 1994, 86:614-619
27. Simpson JF, O'Malley F, Dupont WD, Page DL: Heterogeneous expression of nm23 gene product in noninvasive breast carcinoma. Cancer 1994, 73:2352-2358
28. Douglas-Jones A, Schmid K, Bier B, Horgan K, Lyons K, Dallimore N, Moneypenny I, Jasani B: Metallothionein expression in duct carcinoma in situ of the breast. Hum Pathol 1995, 26:217-222
29. Jensen RA, Page DL, Holt JT: Identification of genes expressed in premalignant breast disease by microscopy-directed cloning. Proc Natl Acad Sci USA 1994, 91:9257-9261
30. O'Malley F, Vnencak-Jones C DuPont W, Parl F, Manning S, Page D: p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast: immunohistochemical and sequencing data. Lab Invest 1994, 71:67-72
31. Poller D, Roberts E, Bell J, Elston C, Blamey R, Ellis I: p53 protein expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c-erb-B-2 protein. Hum Pathol 1993, 24:463-468
32. Zafrani B, Leroyer A, Fourquet A, Laurent M, Trophilme D, Validire P, Sastre-Garau X: Mammographically detected ductal carcinoma in situ of the breast with a new classification: a study of 127 cases: correlation with estrogen and progesterone receptors, p53 and c-eroB-2 proteins, and proliferative activity. Semin Diagn Pathol 1994, 11:208-214
33. Bartek J, Bartkova J, Vojtesek B, Staskova Z, Rejthar A, Kovarik J, Lane DP: Patterns of expression of the p53 tumor suppressor in human breast tissues and tumors in situ and in vitro. Int J Cancer 1990, 46:839-844
34. Leal CB, Schmitt FC, Bento MJ, Maia NC, Lopes CS: Ductal carcinoma in situ of the breast: histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53, and c-erb-B-2. Cancer 1994, 75:2123-2131
35. Tsuda H, Fukotomi T, Hirohashi S: Pattern of gene alteration in intraductal breast neoplasms associated with histological type and grade. Clin Can Res 1995, 1:261-267
36. Schmitt FC, Leal C, Lopes C: p53 protein expression and nuclear DNA content in breast intraductal proliferations. J Pathol 1995, 176:233-241
37. Evans AJ, Pinder SE, Ellis IO, Sibbering DM, Elston CW, Poller DN, Wilson ARM: Correlations between mammographic features of ductal carcinoma in situ (DCIS) and c-erb-2 oncogene expression. Clin Radiol 1994, 49:559-562
38. de Potter CR, Daele SV, de Vijver MJV, Pauwels C, Maertens G, de Boever J, Vandekerckhove D, Roels H: The expression of the neu oncogene product in breast lesions and in normal fetal and adult human tissues. Histopathology 1989, 15:351-362
39. Lodato R, Maguire H, Greene M, Weiner D, LiVolsi V: Immunohistochemical evaluation of c-erb-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Mod Pathol 1990, 3:449-454
40. Gusterson BA, Machin LG, Gullick WJ, Gibbs NM, Powles TJ, Elliot C, Ashley S, Monaghan P, Harrison S: c-erbB-2 expression in benign and malignant breast disease. Br J Cancer 1988, 58:453-457
41. Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, Osborne CK, Tormey DC, McGuire WL: Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 1992, 23:974-979
42. de Vijer MJV, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, Nusse R: Neu-protein overexpression in breast cancer. N Engl J Med 1988, 319:1239-1245
43. Aasmundstad TA, Haugen OA: DNA ploidy in intraductal breast carcinomas. Eur J Cancer 1990, 26:956-959
44. Walker RA, Dearing SJ: Transforming growth factor-β1 in ductal carcinoma in situ and invasive carcinoma of the breast. Eur J Cancer 1992, 28:641-644
45. Poller DN, Snead DRJ, Roberts EC, Galea M, Bell JA, Gilmour A, Elston CW, Blarney RW, Ellis IO: Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotein. Br J Cancer 1993, 68:156-161
46. Giri D, Dundas S, Nottingham J, Underwood J: Oestrogen receptors in benign epithelial lesions and intraduct carcinomas of the breast: an immunohistological study. Histopathology 1989, 15:575-584
47. Bur M, Zimarowski M, Schnitt S, Baker S, Lew R: Estrogen receptor immunohistochemistry in carcinoma in situ of the breast. Cancer 1992, 69:1174-1181